Search
Temocillin
go.drugbank.com/drugs/DB12343ApprovedInvestigationalWithdrawnTemocillin has been investigated in Infection, Liver Dysfunction, and Urinary Tract Infection.
Categories: Heterocyclic Compounds, 2-RingSiponimod
go.drugbank.com/drugs/DB12371ApprovedInvestigational[L12171] This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA … Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS).
Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexOmadacycline
go.drugbank.com/drugs/DB12455ApprovedInvestigationalOmadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent
Categories: P-glycoprotein substratesBelotecan
go.drugbank.com/drugs/DB12459InvestigationalBelotecan has been investigated for the treatment of Epithelial Ovarian Cancer.
Categories: Topoisomerase I Inhibitors, Topoisomerase 1 (TOP1) inhibitorsIbrexafungerp
go.drugbank.com/drugs/DB12471ApprovedIbrexafungerp, also known as SCY-078 or MK-3118, is a novel enfumafungin derivative oral triterpene antifungal approved for the treatment of vulvovaginal candidiasis (VVC), also known as a vaginal yeast … [A235414,L34349] Ibrexafungerp was granted FDA approval on 1 June 2021.[L34349]
Synonyms: (1S,4AR,6AS,7R,8R,10AR,10BR,12AR,14R,15R)-15-((2R)- 2-AMINO-2,3,3-TRIMETHYLBUTOXY)-1,6A,8,10A-TETRAMETHYL-8- ((2R)-3-METHYLBUTAN-2-YL)-14-(5-(PYRIDIN-4-YL)-1H-1,2,4- TRIAZOL-1-YL)-1,6,6A,7,8,9,10,10A,10B, enfumafungin derivative B-(1,3)-D-glucan synthestis inhibitorCategories: P-glycoprotein substrates, Cytochrome P-450 SubstratesAcotiamide
go.drugbank.com/drugs/DB12482InvestigationalAcotiamide has been used in trials studying the treatment of Dyspepsia and Functional Dyspepsia.
Categories: Heterocyclic Compounds, 1-RingMirvetuximab soravtansine
go.drugbank.com/drugs/DB12489ApprovedInvestigational[A254392,L43967] DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1. … 3 prior systemic treatment regimens.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesOzanimod
go.drugbank.com/drugs/DB12612ApprovedInvestigationalOzanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. … [L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020.
Mixtures: ZEPOSIA 7-Day Starter Pack, ZEPOSIA 7-Day Starter PackCategories: Cytochrome P-450 Substrates, P-glycoprotein substratesGivinostat
go.drugbank.com/drugs/DB12645ApprovedInvestigationalGivinostat is a small molecule histone deacetylase (HDAC) inhibitor. … It has been investigated as a treatment for a variety of inflammatory diseases, like Crohn's disease and juvenile idiopathic arthritis, cancers like leukemia and lymphoma, as well as several muscular dystrophies
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 InducersGusperimus
go.drugbank.com/drugs/DB12692InvestigationalGusperimus has been used in trials studying the treatment of Lupus Nephritis, Wegeners Granulomatosis, and Wegener's Granulomatosis.
Categories: Compounds used in a research, industrial, or household setting